Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Astellas Pharma Inc. GLOBAL TOP

Astellas Innovation Management LLC

Main navigation

  • About AIM
  • Team
  • Our Strategy
  • Our Focus
  • Our Project
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
Important Notice

This website may contain information about medicines and their indications that are not approved in your country. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drugs including those under development.

Any information contained herein is not intended to provide medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

News

icon news
News / General News
Feb 19, 2021
Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women
Read More
icon news
News / General News
Feb 15, 2021
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Read More
icon news
News / General News
Feb 15, 2021
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
Read More
icon news
News / General News
Feb 04, 2021
Astellas’ XOSPATA® (gilteritinib) Receives Conditional Approval by China’s National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Read More
icon news
News / General News
Dec 21, 2020
Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Read More
icon news
News / General News
Dec 07, 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
Read More
View more >>

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • TERMS OF USE
  • CONTACT US
Copyright © 2019 Astellas Innovation Management LLC. All Rights Reserved.